Intellia Therapeutics Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$45.00 | Dxsyk | Kqnwsrq |
Intellia Therapeutics’ Pipeline Continues To Make Progress; FVE $85, Shares Very Undervalued
Intellia Therapeutics posted fourth-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our positive outlook and fair value estimate of $85 per share. We view the stock as very undervalued, currently trading in 5-star territory. Collaboration revenue totaled $52 million for the year, representing a 58% increase from 2021. Intellia’s collaboration revenue was primarily driven by its joint venture with AvenCell Therapeutics and revenue from its license agreement with Kyverna Therapeutics.